Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07242469 · ClinicalTrials.gov registry record · Phase 1
A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)
A Phase 1 study of Diabetes Mellitus, Type 2, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
- 4
- Study locations
NCT07242469 is a Phase 1 study of Diabetes Mellitus, Type 2 that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 52 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT07242469, a Phase 1 study of Diabetes Mellitus, Type 2, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to learn about the safety and if people tolerate a study medicine called MK-1403. The study will also measure what happens to MK-1403 in the body of a person with type 2 diabetes (T2D) over time (pharmacokinetic or PK study), and how it affects the amount of high-sensitivity C-reactive protein (hsCRP) in a person's blood.
Conditions Studied
Interventions
- DRUG MK-1403 + additive coformulation
- DRUG Placebo + additive coformulation
Study Locations (4)
Florida
- QPS-MRA, LLC ( Site 0004) - Miami
- Advanced Pharma CR, LLC ( Site 0003) - Miami
California
- ProSciento Inc. ( Site 0001) - Chula Vista
Missouri
- Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0005) - Springfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2025-12-22 |
| Est. Completion | 2026-08-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07242469
The ClinicalTrials.gov registry entry for NCT07242469 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which MK-1403 + additive coformulation is the first listed.
NCT07242469 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Florida, California, Missouri.
Frequently Asked Questions
What is clinical trial NCT07242469 about?
NCT07242469 is a clinical study titled "A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)". The purpose of this study is to learn about the safety and if people tolerate a study medicine called MK-1403. The study will also measure what happens to MK-1403 in the body of a person with type 2 diabetes (T2D) over time (pharmacokinetic or PK study), and how it affects the amount of high-sensiti...
What is the current status of trial NCT07242469?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2025-12-22. Estimated completion is 2026-08-28.
What conditions does trial NCT07242469 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT07242469?
The interventions under investigation include: MK-1403 + additive coformulation (DRUG), Placebo + additive coformulation (DRUG).
Who is sponsoring clinical trial NCT07242469?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07242469 being conducted?
This trial has 4 study locations across California, Florida, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Multiple Dose Study of MK-2828 in Participants With Type 2 Diabetes (MK-2828-003)
RECRUITING · Phase 1
-
Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans
ACTIVE NOT RECRUITING · Phase 1
-
Study of Subcutaneously Administered ENT-03 for the Treatment of Obesity and Diabetes
ACTIVE NOT RECRUITING · Phase 1
-
A Family Dyad-focused Diabetes Self-Management Intervention for African American Adults
ACTIVE NOT RECRUITING · Phase 1
-
Multiple Dose Safety Toelrability, Pharmacokinetics and Midazolam Interaction In Healthy Overweight And Obese Subjects
COMPLETED · Phase 1
-
Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.